IVF · INVO Fertility Inc.
AI read · Neutral
The AI's read
INVO reported Q2 EPS of $0.35 versus an expected $0.65 loss and booked about a $2.5M remeasurement gain, producing $0.89M net income. Clinic Adjusted EBITDA doubled sequentially and management flagged organic growth plus disciplined acquisitions. Shares jumped roughly 59% on the print and volume exploded, so most of the headline upside looks priced into today's move. Revenue was up 17% but missed consensus, so the beat leaned on accounting and one-time items more than top-line surprise. We lean neutral. The catalyst is real but the market already front-ran the news, so any follow-through will need sustained operational proof rather than one-quarter accounting gains.